MIF Inhibitor IPG1094 clinical trials
How each study uses MIF Inhibitor IPG1094 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the MIF Inhibitor IPG1094 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- IPG1094
- 1
Studies by the year they started
3 studies that test it; most in 2021 (1)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2024 | 1 |
| 2026 | 1 |
Who runs them
Industry 3 · Other 0
Nanjing Immunophage Biotech Co., Ltd (3)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test MIF Inhibitor IPG1094.
- Jan 2027IPG1094 Phase I Study for China Healthy ParticipantsPhase 1 · Nanjing Immunophage Biotech Co., Ltd
- Jul 2027Phase I/II Study of IPG1094 in Advanced Solid Tumors PatientsPhase 1/2 · Nanjing Immunophage Biotech Co., Ltd
Studies
Open first, then newest update. How each study uses MIF Inhibitor IPG1094 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- IPG1094 Phase I Study for China Healthy ParticipantsRecruitingPhase 1Nanjing Immunophage Biotech Co., LtdNCT07679113Written as IPG1094 Tablets
- Phase I/II Study of IPG1094 in Advanced Solid Tumors PatientsRecruitingPhase 1/2Nanjing Immunophage Biotech Co., LtdNCT06212076Written as IPG1094
- Phase 1 Study of IPG1094 Safety, Tolerability, and PK in Healthy ParticipantsCompletedPhase 1Nanjing Immunophage Biotech Co., LtdNCT05112159Written as IPG1094 300 mg SAD